Citation Impact
Citing Papers
Nucleic acid detection with CRISPR-Cas13a/C2c2
2017 StandoutScience
HIV Type 1 Isolates from 200 Untreated Individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large Predominance of CRF01_AE and Presence of Major Resistance Mutations to Antiretroviral Drugs
2003 StandoutNobel
Impact of COPD severity on physical disability and daily living activities: EDIP-EPOC I and EDIP-EPOC II studies
2009
No health without mental health
2007 Standout
Transmission of HIV-1 drug resistance
2004
Hepatitis C virus resistance to protease inhibitors
2011
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Role of lipid rafts in virus assembly and budding
2002
COPD Guidelines: A Review of the 2018 GOLD Report
2018 Standout
Epidemiology of COPD
2009 Standout
National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral‐naïve patients
2007
The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection
2011 Standout
Molecular assays for monitoring HIV infection and antiretroviral therapy
2007
Recent progress in the development of coumarin derivatives as potent anti‐HIV agents
2003 Standout
Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology
2006 Standout
Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study
2006
Human immunodeficiency virus type-1 protease inhibitors therapeutic successes and failures, suppression and resistance
2000
ROCR: visualizing classifier performance in R
2005 Standout
Molecular Methods and Platforms for Infectious Diseases Testing
2011
Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy
2005
Pharmacogenomics
2004
Analysis of antiretroviral immunotherapy trials with potentially non‐normal and incomplete longitudinal data
2006
Gene therapy for HIV infection: what does it need to make it work?
2006 StandoutNobel
The challenge of emerging and re-emerging infectious diseases
2004 StandoutNature
Medication adherence in HIV-infected adults
2004
Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
2010
Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel
2003
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
2008 Standout
What We Talk About When We Talk About Fat
2014 Standout
Herb-Drug Interactions
2005 Standout
Approach to the Treatment-experienced patient
2005
Inhibition of HIV replication: A powerful antiviral strategy by IFN-β gene delivery in CD4+ cells
2007 StandoutNobel
Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis
2001
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study
2007 Standout
Not So Different After All: A Comparison of Methods for Detecting Amino Acid Sites Under Selection
2005 Standout
St John's Wort increases expression of P‐glycoprotein: Implications for drug interactions
2002
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
2017 Standout
Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study
2004
Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV*
2002
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis
2005 Standout
Interpreting resistance data for HIV-1 therapy management--know the limitations.
2006
Therapeutic drug monitoring of antiretrovirals for people with HIV
2009
Variants Other than Aspartic Acid at Codon 69 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene Affect Susceptibility to Nucleoside Analogs
2001
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective
2017 Standout
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy
2010
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection
2000
Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype
2002
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
2000
Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings
2006 Standout
The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003
2003 Standout
Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections
2010 Standout
Point-of-Care Diagnostics for Global Health
2008 Standout
Operations Research in Healthcare: a survey
2010 Standout
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors
2004 StandoutNobel
Guidelines for the management of hemophilia
2012 Standout
Works of Pere Simonet being referenced
Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica
2001
Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica
2001
Variable Virological Outcomes According to the Center Providing Antiretroviral Therapy Within the PharmAdapt Clinical Trial
2003
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
1999